[Atypical antipsychotic-induced weight gain].

[Atypical antipsychotic-induced weight gain].

Εμφάνιση άλλων εκδόσεων (1)

Introduction of a new group of antipsychotic drugs, called atypical because of the proprieties differing them from classical neuroleptics, gave hope for the beginning of a new era in treatment of psychoses, including schizophrenia. Different mechanisms of action not only resulted in a broader spectr...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριοι συγγραφείς:	Godlewska, B, Olajossy-Hilkesberger, L, Marmurowska-Michałowska, H, Olajossy, M, Landowski, J
Μορφή:	Journal article
Γλώσσα:	Polish
Έκδοση:	2006

Παρόμοια τεκμήρια

Atypical antipsychotic-induced weight gain
ανά: Godlewska, B, κ.ά.
Έκδοση: (2006)

Antipsychotic-induced weight gain - Pharmacogenetic studies
ανά: Olajossy-Hilkesberger, L, κ.ά.
Έκδοση: (2006)

[Antipsychotic-induced weight gain--pharmacogenetic studies].
ανά: Olajossy-Hilkesberger, L, κ.ά.
Έκδοση: (2006)

Olanzapine-induced weight gain is associated with the -759C/T and -697G/C polymorphisms of the HTR2C gene.
ανά: Godlewska, B, κ.ά.
Έκδοση: (2009)

Polymorphisms of the histamine receptor (H1HR) gene are not associated with olanzapine-induced weight gain.
ανά: Godlewska, B, κ.ά.
Έκδοση: (2013)

Effectiveness of long-acting injectable risperidone in the Korean schizophrenia patients
ανά: Ciwoniuk, M, κ.ά.
Έκδοση: (2007)

Polymorphisms of the 5-HT2A receptor gene and clinical response to olanzapine in paranoid schizophrenia.
ανά: Olajossy-Hilkesberger, L, κ.ά.
Έκδοση: (2011)

Ser9Gly polymorphism of the DRD3 gene is associated with worse premorbid social functioning and an earlier age of onset in female but not male schizophrenic patients.
ανά: Godlewska, B, κ.ά.
Έκδοση: (2010)

Atypical antipsychotics (multiple letters)
ανά: McKenna, P, κ.ά.
Έκδοση: (2002)

Atypical antipsychotics in the treatment of schizophrenia - Reply
ανά: Geddes, J, κ.ά.
Έκδοση: (2001)

Conventional vs. atypical antipsychotic medications.
ανά: Barbui, C, κ.ά.
Έκδοση: (2006)

Atypical antipsychotics and anorexia nervosa: a review.
ανά: McKnight, R, κ.ά.
Έκδοση: (2010)

A systematic review of the use of atypical antipsychotics in autism.
ανά: Barnard, L, κ.ά.
Έκδοση: (2002)

Comparison of systematic and narrative reviews: the example of the atypical antipsychotics.
ανά: Cipriani, A, κ.ά.
Έκδοση: (2003)

Associated mortality risk of atypical antipsychotic medication in individuals with dementia
ανά: Phiri, P, κ.ά.
Έκδοση: (2022)

Atypical antipsychotics in bipolar disorder: systematic review of randomised trials
ανά: Derry, S, κ.ά.
Έκδοση: (2007)

Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis.
ανά: Geddes, J, κ.ά.
Έκδοση: (2000)

Attitudes to atypical and conventional antipsychotic drug treatment in clinicians participating in the cutlass study.
ανά: Lloyd, H, κ.ά.
Έκδοση: (2005)

Generating evidence to inform policy and practice: the example of the second generation "atypical" antipsychotics.
ανά: Geddes, J
Έκδοση: (2003)

Atypical antipsychotics in the treatment of schizophrenia: Systematic review, meta-regression and evidence-based treatment recommendations
ανά: Geddes, J, κ.ά.
Έκδοση: (2000)

REalist Synthesis Of non-pharmacologicaL interVEntions for antipsychotic-induced weight gain (RESOLVE) in people living with severe mental illness (SMI)
ανά: Maidment, ID, κ.ά.
Έκδοση: (2022)

Weight gain with antipsychotic drugs: the role of the 5-HT2C receptor (HTR2C) and other genes.
ανά: Harrison, P
Έκδοση: (2005)

Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment.
ανά: Lewis, S, κ.ά.
Έκδοση: (2006)

Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment
ανά: Lewis, S, κ.ά.
Έκδοση: (2006)

Indicators of the persistent pro-inflammatory activation of the immune system in depression
ανά: Cubała, W, κ.ά.
Έκδοση: (2006)

[Indicators of the persistent pro-inflammatory activation of the immune system in depression].
ανά: Cubała, W, κ.ά.
Έκδοση: (2006)

The psychological journey of weight gain in psychosis
ανά: Waite, F, κ.ά.
Έκδοση: (2022)

Gaining weight the right way
ανά: The Star,
Έκδοση: (2013)

[Intravenous clomipramine for depressive disorders].
ανά: Landowski, J, κ.ά.
Έκδοση: (2002)

Intravenous clomipramine for depressive disorders
ανά: Landowski, J, κ.ά.
Έκδοση: (2002)

Atypical presentation of an atypical pneumonia: a case report
ανά: Alvin Oliver Payus, κ.ά.
Έκδοση: (2021)

Lack of adjustment for nutrition and undiagnosed Diabetes Mellitus (DM) type 2 in retrospective studies evaiuating the link between DM type 2 and atypical antipsychotics
ανά: Cerri, K, κ.ά.
Έκδοση: (2004)

Safety of antipsychotics in people with intellectual disability
ανά: Frighi, V, κ.ά.
Έκδοση: (2011)

Safety of antipsychotics in people with intellectual disability.
ανά: Frighi, V, κ.ά.
Έκδοση: (2011)

Interventions for preventing weight gain after smoking cessation
ανά: Hartmann-Boyce, J, κ.ά.
Έκδοση: (2021)

Does slow and steady win the race? Rates of antipsychotic discontinuation, antipsychotic dose, and risk of psychotic relapse
ανά: McCutcheon, RA, κ.ά.
Έκδοση: (2023)

New generation versus conventional antipsychotics.
ανά: Geddes, J, κ.ά.
Έκδοση: (2003)

Managing smoking cessation‑related weight gain.
ανά: Aveyard, P, κ.ά.
Έκδοση: (2012)

Prebiotic attenuation of olanzapine-induced weight gain in rats: analysis of central and peripheral biomarkers and gut microbiota
ανά: Kao, A, κ.ά.
Έκδοση: (2018)

Interventions for preventing weight gain after smoking cessation.
ανά: Parsons, A, κ.ά.
Έκδοση: (2009)